complications (8) (9) (10) (11) (12) (13) (14) (15) . Indeed, we, along with others, have previously shown that AGEs could elicit a brisk angiogenic response, at least in part, by inducing autocrine production of vascular endothelial growth factor (VEGF), which is an important mediator in the development and progression of diabetic retinopathy (16) (17) (18) .
AGEs exert pleiotropic actions on cells by inducing the generation of intracellular reactive oxygen species (ROS) (19) . ROS in turn activate the Ras proto-oncogene and its downstream effectors that are important for both proliferative and differentiative responses.
Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors (20) . It was first purified from the conditioned media of human retinal pigment epithelial cells as a factor with potent neuronal differentiating activity (20) .
Recently, PEDF has been shown to be a highly effective inhibitor of angiogenesis in cell culture and animal models. PEDF inhibits the growth and migration of cultured endothelial cells (ECs), and it potently suppresses ischemia-induced retinal neovascularization (21, 22) . PEDF levels in aqueous humor or vitreous are decreased in diabetic patients, especially with proliferative retinopathy (23) (24) (25) . These observations suggest that the loss of PEDF activity in the eye may contribute to the pathogenesis of proliferative by guest on http://www.jbc.org/ Downloaded from diabetic retinopathy. However, the protective role of PEDF against retinal vascular hyperpermeability, the characteristic feature of early diabetic retinopathy, remains to be elucidated. In this study, we have investigated whether PEDF could inhibit the AGE-induced retinal vascular hyperpermeability and the mechanism by which it might achieve this beneficial effect.
MATERIALS AND METHODS

Materials
Diphenylene iodonium (DPI), lucigenin and NADPH were purchased from Sigma (St. Louis, MO). Polyclonal antibodies (Abs) against rat VEGF were purchased from R&D systems (Genzyme-Techne, Minneapolis, MN). Protease inhibitor cocktails were from Nakalai Tesque (Kyoto, Japan).
Purification of PEDF Proteins
PEDF proteins were prepared and purified as described previously (12) . SDS-PAGE analysis of purified PEDF proteins revealed a single band with a molecular weight of about 50 kDa, which showed positive reactivity with monoclonal Ab against human PEDF (Transgenic, Kumamoto, Japan).
Preparations of AGEs
AGE-bovine serum albumin (BSA) was prepared as described previously (12) . Briefly, BSA (50 mg/ml) was incubated under sterile conditions with 0.1 M D-glyceraldehyde in 0.2 M NaPO 4 buffer (pH 7.4) for 7 days. Then unincorporated sugars were removed by dialysis against phosphate-buffered saline. Control non-glycated BSA was incubated in the same conditions except for the absence of reducing sugars. Preparations were tested for endotoxin using Endospecy ES-20S system (Seikagaku Co., Tokyo, Japan); no endotoxin was detectable.
Preparations of AGE-Rich Serum Fractions from Diabetic Patients on Hemodialysis
Serum AGE fractions were obtained from normal volunteers (Normal) and diabetic patients with hemodialysis (DM-AGEs) as described previously (26) . Briefly, 10 ml of serum from each of 4 normal individuals and from 11 type 2 diabetic patients with end-stage renal disease on hemodialysis were concentrated by lyophilization and dissolved in 2 ml of distilled water. These solutions were applied to a Sephacryl S-200 column (1.5 x 110 cm), which was equilibrated with PBS (pH 7.4) and eluted with the same buffer (fraction size: 1.5 ml, flow rate: 10 ml/h) in a cold room. Each fraction was monitored for absorbance at 280 nm and the AGE concentration of each fraction was measured by a competitive ELISA as described below. Preparations were passed through Zeta-Pore filter to remove endotoxin. No endotoxin was detectable. AGErich serum fractions obtained from diabetic patients on hemodialysis and normal volunteers contained 176.1 and 28.5 g/ml AGEs, respectively. Clinical characteristics of 11 type 2 diabetic patients were shown in Table 1 .
Enzyme-Linked Immunosorbent Assay (ELISA) for AGEs
Measurement of AGEs was performed with a competitive ELISA as described previously (27) . Briefly, 96 well microtiter plates were coated with 0.1 g/ml AGE-BSA. Then, test samples (50 l) were added to each well as a competitor for 50 l of polyclonal Abs directed against AGE-BSA (1:1000), followed by incubation for 2 h at room temperature with gentle shaking on a horizontal rotary shaker. After incubating each well with alkaline phosphatase-conjugated anti-rabbit IgG, p-nitrophenyl phosphate was added as a colorimetric substrate. Then the plate was read at 405 nm using a microplate reader.
In Vitro-Prepared AGE Treatments of Normal Rats
Nine wk-old normoglycemic Sprague-Dawley (SD) rats were injected intravenously with 1 mg AGE-BSA or non-glycated BSA in the presence or absence of 10 g PEDF proteins or 10 g Abs against rat VEGF every day for up to 10 days. The rats were sacrificed 1-2 h after injection on the final day. This AGE administration increases serum AGE levels by about 2-fold, compared with non-glycated BSA injection (33.4±1.6 vs 18.7±0.5 g/ml). We have recently found that serum level of AGEs in diabetic rats (GotoKakizaki rats at 14 weeks old) was 32.8±7.1 g/ml. Therefore, the serum AGE concentrations obtained by the AGE injection were comparable to those of diabetic rats. All animal procedures were conducted according to the guidelines provided by the Kurume University Institutional Animal Care and Use Committee under an approved protocol.
Leakage of FITC-Conjugated Dextran from Retinal Vasculature
Leakage of FITC-conjugated dextran from retinal vasculature was determined by the method of Stitt et al (18) . Briefly, rats were deeply anesthetized, and then FITC-conjugated dextran (40 kDa, Sigma) was injected into the inferior vena cava. After the tracer was allowed to circulate, the eyes were enucleated and immediately fixed in 4 % paraformaldehyde (Sigma). The retinas were imaged by a laserscanning confocal microscope.
Quantification of Blood Retinal Barrier (BRB)
Breakdown BRB breakdown quantification was determined by the method of Adamis et al (28) . Briefly, after deep anesthesia, the rats received intravenous injection with FITC-conjugated dextran (4.4 kDa, Sigma). After 10-15 minutes, a blood sample was collected and then each rat was perfused with PBS. After perfusion, the retinas were carefully removed, weighted, and homogenized to extract the FITC-conjugated dextran. BRB breakdown was calculated using the following equation:
Retinal FITC-dextran (mg)/retinal weight (g) Plasma FITC-dextran concentration (mg/mL) x circulation time (hour)
Effects of AGE-Rich Serum Fractions on Retinal Vascular Permeability
Nine wk-old SD rats were injected intravenously with AGE-rich serum fractions derived from normal volunteers (Normal) or diabetic patients with hemodialysis (DM-AGEs) in the presence or absence of 10 g PEDF proteins or 77 g polyclonal anti-human PEDF Abs. After every day-injection for 5 days, the rats were sacrificed and retinal permeability and BRB breakdown were analyzed.
Cells
Human adult skin microvascular ECs were cultured in endothelial basal medium supplemented with 5 % fetal bovine serum, 0.4 % bovine brain extracts, 10 ng/ml human epidermal growth factor and 1 g/ml hydrocortisone according to the supplier's instructions (Clonetics Corp., San Diego, CA). AGE treatment was carried out in a medium lacking epidermal growth factor and hydrocortisone. Cells at 3-5 passages were used for the experiments.
Quantitative Real-Time Reverse TranscriptionPolymerase Chain Reactions (RT-PCR)
Poly(A) + RNAs were isolated from ECs or enucleated eyes as described previously (16) . Quantitative real-time RT-PCR was performed using Assay-on-Demand and TaqMan 5 fluorogenic nuclease chemistry (Applied Biosystems, Foster city, CA) according to the manufacturer's recommendation. IDs of primers for human p22phox, human gp91phox, human VEGF, rat p22phox, rat gp91phox, and rat VEGF gene were Hs00164370_m1, Hs00166163_m1, Hs00173626_m1, Rn00577357_m1, Rn00576710_m1, and Rn00582935_m1, respectively.
Immunohistochemistry
Rat eyes were removed and fixed for 1 day in 4 % paraformaldehyde. Then the eyes were embedded in paraffin wax for sectioning. Five m paraffin sections were incubated with polyclonal Abs raised against human PEDF (4 g/ml; Santa Cruz Biotechnology, Santa Cruz, CA) or monoclonal Abs raised against 8-hydroxydeoxyguanosine (8-OHdG) (10 g/ml; Japan Institute for the Control of Aging, Shizuoka, Japan). After exposure to peroxidaselabelled secondary anti-rabbit Abs, the sections were incubated with 3,3'-diaminobenzidine solution (Nichirei, Tokyo, Japan) and then counterstained with methyl green for visualizing PEDF or 8-OHdG immunoreactivity. The immunoreactivity was measured with microcomputer-assisted NIH Image.
Measurement of Transendothelial Electrical Resistance (TER)
Effects of PEDF on barrier function of ECs were assessed by measurement of TER using electric cell substrate impedance sensing (Applied Biophysics) according to the method of Becker et al (29) . Briefly, the cells were seeded onto gold microelectrodes (Applied Biophysics) and grown to confluence for 2 days. Cells were washed three times with serum-free endothelial basal medium and then were connected to the impedance sensing system to measure the TER baseline. The applied alternating current (1 µA) was clamped so that impedance (resistance) was directly related to changes in voltage, which was measured with a locked-in amplifier. Data from the electrical resistance experiments (ohms) were obtained over the experimental time course at 5-min intervals. Resistance values for each microelectrode were normalized as the ratio of measured resistance to baseline resistance and plotted as a function of time.
NADPH Oxidase Assay
ECs were treated with 100 g/ml of AGE-BSA or non-glycated BSA in the presence or absence of 10 nM PEDF for 24 h, and then and then the cells were suspended in homogenization buffer (20 mM Hepes, pH 7.0, 100 mM KCl, and 1 mM EDTA containing protease inhibitor cocktails). NADPH oxidase activity of the cell homogenate was measured by luminescence assay in 50 mM phosphate buffer, pH 7.0, containing 1 mM EGTA, 150 mM sucrose, 5 M lucigenin as the electron acceptor, and 100 M NADPH as a substrate according to the methods of Griendling et al (30) .
Preparations of Abs Directed against In VitroPrepared AGE-BSA
Polyclonal Abs directed against in vitro-modified AGE-BSA were prepared as described previously (27) . We have previously shown that the Abs did not cross-react with several structurally identified AGE-modified BSA including pyrraline-BSA, pentosidine-BSA, argpyrimidine-BSA, 3-deoxyglucosone imidazolone-BSA, carboxymethyllysine-BSA, carboxyethyllysine-BSA, glyoxal-lysine dimmer, or methyglyoxallysine dimmer (13, 27) .
Preparations of Antiserum Directed against Receptor for AGEs (RAGE)
Antiserum directed against human RAGE for neutralizing assays, which recognizes the amino acid residues 167 to 180 of human RAGE protein, was prepared as described previously (31) .
Intracellular ROS Generation
ECs were treated with various concentrations of AGE-BSA or non-glycated BSA in the presence or absence of 10 nM PEDF, 50 nM DPI, 10 g/ml Abs directed against AGEs, or 0.1 % anti-RAGE serum for 24 h. The intracellular formation of ROS was detected by using the fluorescent probe CM-H 2 DCFDA (Molecular Probes Inc., Eugene, OR) as described previously (15) .
Superoxide Generation
ECs were treated with serum AGE fractions in the presence or absence of 10 nM PEDF for 24 h, and then the cells were incubated with phenol red free DMEM containing 3 mol/l dihydroethidium (DHE) (Molecular Probes Inc., Eugene, OR). After 30 minutes, fluorescence intensity was measured, and the cells were imaged by a laserscanning confocal microscope.
Assay for Ras Activation
ECs were treated with 100 g/ml of AGE-BSA or non-glycated BSA in the presence or absence of 10 nM PEDF or 1 mM NAC for 24 h. Ras activity then was measured using a Ras Activation Assay Kit (Upstate Biotechnology Inc., Lake Placid, NY) following the manufacturer's instructions.
Transfection of Dominant-Negative Mutant Vector
ECs were transiently transfected with a dominant-negative human Ras mutant (DN-Ras) vector or an empty vector (Mock) as described previously (17) .
Measurement of NF-B Activity
ECs were transiently transfected with plasmids containing the NF-B promoter attached upstream to the luciferase reporter gene. Luciferase activity was measured as described previously (17) .
Statistical Analysis
All values were presented as means ± SE. Oneway ANOVA followed by the Scheffe F test, was performed for statistical comparisons. P<0.05 was considered significant.
RESULTS
Anti-Vasopermeability Effects of PEDF In Vivo
We used glyceraldehyde-modifed AGE-BSA for the present experiments because we have previously shown that this type of AGEs could elicit a brisk angiogenic response by inducing autocrine production of VEGF, also known as a vascular permeability factor (17, 32, 33) . In order to further investigate the molecular mechanism by which PEDF inhibited the AGEinduced vascular permeability, we conducted the following experiments using microvascular ECs.
Molecular Mechanism for the Suppression by PEDF of the Vasopermeability Effects of AGEs
In vivo we showed that PEDF inhibited upregulation of mRNA levels for p22phox and gp91phox. Therefore, we first addressed this issue in vitro. As shown in Figure 3A , AGEs upregulated mRNA levels of p22phox and gp91phox, which was significantly blocked by PEDF. Moreover, PEDF inhibited the increase of NADPH activity induced by AGEs ( Figure 3B ).
Ten nM PEDF alone did not affect the NADPH oxidase activity in ECs (data not shown).
AGEs exert a pleiotropic action on multiple cell functions through the generation of ROS (13- 
